Compare LAW & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LAW | CRVS |
|---|---|---|
| Founded | 2013 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 466.2M | 546.7M |
| IPO Year | 2021 | 2016 |
| Metric | LAW | CRVS |
|---|---|---|
| Price | $6.35 | $22.24 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $9.00 | ★ $17.75 |
| AVG Volume (30 Days) | 143.9K | ★ 5.6M |
| Earning Date | 02-19-2026 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $152,677,000.00 | N/A |
| Revenue This Year | $8.51 | N/A |
| Revenue Next Year | $8.39 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 6.33 | N/A |
| 52 Week Low | $3.31 | $2.54 |
| 52 Week High | $9.11 | $22.10 |
| Indicator | LAW | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | 29.11 | 91.59 |
| Support Level | $7.11 | $6.46 |
| Resistance Level | $7.52 | $7.18 |
| Average True Range (ATR) | 0.34 | 1.42 |
| MACD | -0.17 | 1.56 |
| Stochastic Oscillator | 10.86 | 90.50 |
CS Disco Inc provides a cloud-native, artificial intelligence-powered legal solution that simplifies discovery, legal document review, and case management for enterprises, law firms, legal services providers, and governments. Its revenue-generating activities directly relate to the sale and support of legal solutions. It has two primary types of contractual arrangements: usage-based and subscription solutions. The usage-based revenue is derived from contracts under which customers are billed monthly based on their usage. Subscription revenue is derived from contracts where customers are contractually committed to a minimum data volume over a period of time.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).